March 12, 2026. 7 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score.
IRS Files First Response to Common Industry 280E Arguments | Harris Beach Murtha – JDSupra
This article discusses IRS responses to Section 280E tax deduction arguments commonly used by cannabis businesses, relevant to clinicians advising patients on industry economics.
Tilray Jumps 50% in Cannabis Rally After Trump Posts CBD Video – MSN
Stock market movement in cannabis company following promotional CBD content, potentially relevant for clinicians monitoring industry developments and marketing claims in the sector.
Marijuana MSOs’ 280E bill grows to $1.6 billion as IRS fights tax gambit – MJBizDaily
Article Summary
Cannabis multistate operators face $1.6 billion in accumulated IRS tax bills under Section 280E, which clinicians may track as it affects industry financial viability and patient access.
Ascend Wellness Saw Higher Operating Loss in Q4 – New Cannabis Ventures
Summary
This article reports Ascend Wellness’s Q4 financial results and regulatory approval for a New Jersey social equity store, which may interest clinicians tracking market consolidation and state licensing trends.
North Charleston man arrested on several drug charges, police say – WCSC
A 28-year-old was arrested on multiple drug charges including marijuana possession with intent to distribute, representing routine law enforcement activity with minimal clinical relevance.
100 pounds of marijuana, 10K THC vapes seized after chase in Indiana: officials | FOX 32 Chicago
Law enforcement seized 100 pounds of cannabis and 10,000 THC vape cartridges during a police chase, illustrating the scale of illicit cannabis distribution networks affecting public safety.
Cairo man arrested after police discover 14 pound shipment of marijuana – WCTV
Summary
Local law enforcement arrested a Cairo resident following discovery of a 14-pound marijuana shipment, illustrating ongoing illicit supply chain enforcement in the region.
Digest-Level Clinical Commentary
Clinical Reflection
These items illustrate the widening bifurcation in cannabis medicine: while legitimate medical applications continue gaining regulatory attention (evidenced by rescheduling discussions and clinical interest in cannabinoid therapeutics), the illicit market remains robust and lucrative, suggesting that medical legitimacy alone won’t eliminate black market competition or resolve the persistent tax and banking barriers that constrain licensed practitioners. As clinicians, we must recognize that cannabis medicine’s clinical credibility depends on rigorous evidence generation and patient safety protocols, not market momentum or promotional claims about endocannabinoid “restoration” that outpace current pharmacological understanding. The $1.6 billion in accumulated tax disputes underscores that regulated practice exists in legal and financial complexity that will ultimately shape which delivery systems, formulations, and patient populations we can responsibly serve in clinical settings.
Clinical Perspective
These items illustrate the ongoing tension between cannabis’s evolving regulatory status and its current legal classification, with significant financial and enforcement implications across multiple sectors. The prominence of tax and rescheduling discussions alongside seizure reports reflects the dual reality that cannabis remains federally scheduled while gaining acceptance through state programs and clinical interest. Regulatory uncertainty continues to create substantial compliance burdens for legitimate operators while black market activity persists, suggesting that the current legal framework creates neither sufficient legitimacy for compliant businesses nor effective deterrence for illicit supply chains.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
